These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 16859203)

  • 1. Infection and inflammation in patients on dialysis: an underlying contributor to anemia and epoetin alfa hyporesponse.
    Breiterman-White R
    Nephrol Nurs J; 2006; 33(3):319-22; quiz 323-4. PubMed ID: 16859203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing hyporesponse to Epoetin alfa: an algorithm approach: case study of the anemic patient.
    Wingard R
    Nephrol Nurs J; 2000 Oct; 27(5):517-20. PubMed ID: 16649327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein and anemia: implications for patients on dialysis.
    Breiterman-White R
    Nephrol Nurs J; 2006; 33(5):555-8. PubMed ID: 17044439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timely correction of anemia at the initiation of dialysis. Case study of the anemic patient.
    Breiterman-White R
    Nephrol Nurs J; 2002 Oct; 29(5):469-72. PubMed ID: 12434453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supporting epoetin alfa stimulated erythropoiesis: identifying appropriate iron levels: case study of the anemic patient.
    Sasak C
    Nephrol Nurs J; 2000 Dec; 27(6):612-5. PubMed ID: 16649342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing the anemia of end-stage renal disease after hospitalization.
    Krishnan M; Adams E
    Nephrol Nurs J; 2004; 31(5):541-4. PubMed ID: 15518256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisions in the prescribing information for Epoetin alfa: implications for nephrology nurses and patients on dialysis.
    Hayslip D
    Nephrol Nurs J; 2008; 35(2):163-7. PubMed ID: 18472685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infection and inflammation in dialysis patients: impact on laboratory parameters and anemia. Case study of the anemic patient.
    Szymanski N
    Nephrol Nurs J; 2001 Jun; 28(3):337-40. PubMed ID: 12143455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
    Larson K
    Nephrol Nurs J; 2008; 35(2):184-93; quiz 194-5. PubMed ID: 18472686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anemia management practices in peritoneal dialysis patients. Case study of the anemic patient.
    MacCracken MA
    Nephrol Nurs J; 2001 Aug; 28(4):435-8. PubMed ID: 12143466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anemia management protocols: providing consistent hemoglobin outcomes.
    Michael M
    Nephrol Nurs J; 2005; 32(4):423-6. PubMed ID: 16180783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updating practices in an evolving IV iron and anemia environment: practical solutions.
    Amerling R; Easom A; Juergensen P
    Nephrol Nurs J; 2007; 34(5):533-41; quiz 542-3. PubMed ID: 18041456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tools for analyzing trends in anemia management case study of the anemic patient.
    Aiello J
    Nephrol Nurs J; 2000 Feb; 27(1):57-60. PubMed ID: 10852692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
    Więcek A; Ahmed I; Scigalla P; Koytchev R
    Adv Ther; 2010 Dec; 27(12):941-52. PubMed ID: 20972656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The challenges of using serum ferritin to guide i.v. iron treatment practices in patients on hemodialysis with anemia.
    Easom A
    Nephrol Nurs J; 2006; 33(5):543-51; quiz 552-3. PubMed ID: 17044438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of response to various erythropoiesis--stimulating proteins using anemia management software.
    Waterschoot M
    J Ren Care; 2007; 33(2):78-82. PubMed ID: 17702511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comorbid diseases in patients on dialysis: the impact on anemia.
    Brattich M
    Nephrol Nurs J; 2007; 34(1):72-5, 98. PubMed ID: 17345694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.